TLR9 and Obesity: Conversely, administration of TLR9 antagonist (iODN2088) to HFD-fed mice attenuated metabolic tissue inflammation, improved glucose metabolism (14), and ameliorated manifestation of liver steatosis (15), confirming the crucial role of TLR9 in obesity-mediated pathogenesis.